GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO BTA) » Definitions » Cyclically Adjusted Price-to-FCF

Vicore Pharma Holding AB (OSTO:VICO BTA) Cyclically Adjusted Price-to-FCF : (As of Jul. 14, 2025)


View and export this data going back to . Start your Free Trial

What is Vicore Pharma Holding AB Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vicore Pharma Holding AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Vicore Pharma Holding AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Cyclically Adjusted Price-to-FCF Chart

Vicore Pharma Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vicore Pharma Holding AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vicore Pharma Holding AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Vicore Pharma Holding AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Vicore Pharma Holding AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Vicore Pharma Holding AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Vicore Pharma Holding AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-7.574/132.8245*132.8245
=-7.574

Current CPI (Mar. 2025) = 132.8245.

Vicore Pharma Holding AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.000 99.995 0.000
201509 0.000 100.228 0.000
201512 0.000 100.276 0.000
201603 -0.622 100.751 -0.820
201606 -0.473 101.019 -0.622
201609 -0.318 101.138 -0.418
201612 -0.409 102.022 -0.532
201703 -0.535 102.022 -0.697
201706 -0.747 102.752 -0.966
201709 -0.659 103.279 -0.848
201712 -0.516 103.793 -0.660
201803 -0.620 103.962 -0.792
201806 0.383 104.875 0.485
201809 -0.415 105.679 -0.522
201812 -2.255 105.912 -2.828
201903 -1.628 105.886 -2.042
201906 -1.974 106.742 -2.456
201909 -1.869 107.214 -2.315
201912 -2.181 107.766 -2.688
202003 -2.576 106.563 -3.211
202006 -2.270 107.498 -2.805
202009 -2.265 107.635 -2.795
202012 -3.439 108.296 -4.218
202103 -4.195 108.360 -5.142
202106 -6.494 108.928 -7.919
202109 -6.015 110.338 -7.241
202112 -6.620 112.486 -7.817
202203 -6.302 114.825 -7.290
202206 -5.653 118.384 -6.343
202209 -5.870 122.296 -6.375
202212 -8.819 126.365 -9.270
202303 -6.834 127.042 -7.145
202306 -6.074 129.407 -6.234
202309 -3.111 130.224 -3.173
202312 -5.934 131.912 -5.975
202403 2.030 132.205 2.040
202406 -4.359 132.716 -4.363
202409 -7.679 132.304 -7.709
202412 -4.501 132.987 -4.495
202503 -7.574 132.825 -7.574

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vicore Pharma Holding AB  (OSTO:VICO BTA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Vicore Pharma Holding AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicore Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines